By Abigail Townsend
Date: Wednesday 20 Oct 2021
(Sharecast News) - Biogen raised its full-year earnings guidance on Wednesday, despite weak sales of breakthrough Alzheimer's drug Aduhelm.
Currency | US Dollars |
Share Price | $ 149.61 |
Change Today | $ -1.36 |
% Change | -0.90 % |
52 Week High | $191.56 |
52 Week Low | $118.84 |
Volume | 1,600,465 |
Shares Issued | 145.80m |
Market Cap | $21,813m |
RiskGrade | 259 |
Time | Volume / Share Price |
15:59 | 100 @ $149.60 |
15:59 | 100 @ $149.66 |
15:59 | 100 @ $149.65 |
15:59 | 100 @ $149.65 |
15:59 | 255 @ $149.65 |
You are here: research